Zymeworks Inc., was incorporated under the laws of the State of Delaware in June 2022. The company is a global biotechnology company that manages a portfolio of licensed medical assets and develops novel biotherapeutic product lines for cancer, inflammation and autoimmune diseases. Its strategy combines royalty aggregation, strategic acquisitions and internal innovation, and is underpinned by its proprietary multispecific antibody and antibody-drug conjugate technology platform.
